• Rhodamine B Workflows for Bioimaging and Assays

  2026-09-04

  Rhodamine B combines practical solvent flexibility with a strong optical readout for cell labeling, microscopy, tracer studies, and fluorescence-based assay development. This guide translates a trypsin-responsive nanomedicine study into disciplined imaging controls, workflow parameters, and troubleshooting strategies without confusing fluorescence localization with therapeutic efficacy.

• N-MYC/eIF4G1 Survival Axis in inv(16) AML

  2026-09-03

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and show that N-MYC sustains inv(16) acute myeloid leukemia through the translation-initiation factor eIF4G1. The study connects CBFβ-SMMHC-dependent transcriptional deregulation with leukemic survival and provides a mechanistic framework for acute myeloid leukemia research and target validation.

• Arsenic, MMP-2/MMP-9, and BBB Dysfunction

  2026-09-03

  The reference study links sodium arsenite-induced cognitive impairment in male mice to MMP-2/MMP-9-associated blood–brain barrier disruption, tight-junction loss, and hippocampal neuronal apoptosis. Its doxycycline intervention provides pharmacological evidence that preserving barrier integrity may lessen arsenic-related behavioral deficits, while also highlighting the limits of broad MMP inhibition as a mechanistic test.

• CDK9 inhibitor A3294: Protocol and QC Guide

  2026-09-02

  CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for studying CDK9-dependent transcription elongation and P-TEFb activity. It is suited to controlled biochemical and MT4 HIV-1 research workflows, but not to broad CDK inhibition, therapeutic interpretation, or long-term storage of prepared solutions.

• Resveratrol: An Assay-First SIRT1 Framework

  2026-09-02

  Resveratrol is examined as a SIRT1 activator through an assay-first framework for separating mitochondrial rescue from nonspecific antioxidant or cytotoxic effects. The article translates prion-stressed N2a findings into practical experimental decisions, controls, and storage guidance.

• 1-myristoylglycerophosphocholine in Fibrosis Research

  2026-09-01

  Use 1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, as a defined lysophospholipid stimulus for smooth muscle assays and epithelial–fibroblast fibrosis models. This workflow emphasizes solvent control, species-specific dosing, and mechanistic validation rather than treating a complex LysoPC mixture as a single signal.

• Dextrose for Hypoxia and Immunometabolism Assays

  2026-09-01

  Dextrose (D-glucose) is more than a routine nutrient in hypoxia and immunometabolism experiments. This guide explains how to use it as a controlled metabolic variable, connect glucose availability to tumor–immune interactions, and design more interpretable assays.

• Resazurin Cell Viability Assay Kit for Bone Research

  2026-08-31

  Build a viability checkpoint into Wnt and osteoblast experiments without washing or sacrificing cells. This workflow shows how a sensitive fluorescent cell viability assay can distinguish treatment-related growth effects from changes in osteogenic biology.

• Cell Tumbling Drives Stem Cell Differentiation

  2026-08-30

  Ayushman et al. identify cell tumbling as a rapid three-dimensional movement that enables mesenchymal stem cells to deform sliding hydrogels and enhances chondrogenic differentiation. Their experiments connect this behavior to nuclear mechanotransduction and reduced global chromatin accessibility, suggesting that short-timescale niche deformation can regulate cell fate over much longer periods.

• ECL Chemiluminescent Substrate Detection Kit

  2026-08-29

  A scenario-based guide to selecting and optimizing the ECL Chemiluminescent Substrate Detection Kit, SKU K1129, for HRP-based Western blot and chemiluminescent immunoassay workflows. It connects assay readouts with mechanistic studies of ferroptosis while separating documented product specifications from laboratory recommendations.

• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-08-29

  The reference study combines a macrophage phenotypic screen with TAM-avid nanodelivery to suppress SPP1, a myeloid-cell program associated with adverse tumor biology. Its lead compound, CANDI460, reduced SPP1 expression in vitro and in vivo and produced tumor remissions in several murine models, providing a framework for pharmacologically reprogramming tumor-associated macrophages.

• ICG001: Wnt/β-catenin Pathway Inhibitor Workflows

  2026-08-28

  ICG001 provides a selective way to test whether β-catenin requires CBP-dependent transcription, rather than simply measuring total β-catenin abundance. This workflow connects cancer, stem-cell, and fibrosis assays with practical controls for formulation, dosing, imaging, and interpretation.

• 3-Deazaneplanocin (DZNep) Workflow Guide

  2026-08-28

  Build reproducible DZNep experiments for apoptosis induction in AML cells, hepatocellular carcinoma research, and tumor-initiating cell assays. This guide combines dose–time design, epigenetic target engagement, model stratification, and troubleshooting for stronger mechanistic conclusions.

• Penicillin G Sodium: From Cell Wall to Translation

  2026-08-27

  A mechanistic and strategic guide to using Penicillin G Sodium in translational research, from bacterial cell wall targeting and exposure design to renal transporter context, clinical relevance, sourcing, and evidence-bounded study planning.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-27

  Grafton and colleagues combined human iPSC-derived cardiomyocytes, high-content imaging, and deep learning to identify cardiotoxic phenotypes across compound libraries. The study provides a scalable, target-agnostic framework for detecting liability earlier in drug discovery, while also clarifying why phenotypic signals require mechanistic and electrophysiological follow-up.

456 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page